Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience

Urology

Volumn 51, Issue 1, 1998, Pages 137-144

  Grossfeld, Gary D ^a   Small, Eric J ^a   Carroll, Peter R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN AGONIST; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0031891154     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00488-3     Document Type: Article

References (17)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Catalona WJ, Smith DS, Ratliff TL, and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
3. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 157: 439-444, 1997.
4. Townsend MF, Sanders WH, Northway RO, and Graham SD Jr.: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79: 545-550, 1997.
5. Strum SB, McDermed JE, Scholz MC, Tisman G, and Johnson H: Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO) (abstract). J Urol 157: 232, 1997.
6. Kozlowski JM, Ellis WJ, and Grayhack JT: Advanced prostatic carcinoma, early versus late endocrine therapy. Urol Clin North Am 18: 15-24, 1991.
7. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, and Lawson D: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282, 1990.
8. Rennie PS, Bruchovsky N, and Coldman AJ: Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Molec Biol 37: 843-847, 1990.
9. Furuya Y, Sato N, Akakura K, Ichikawa T, Suzuki N, Sato R, and Shimazaki J: Paracrine growth stimulation of androgen-responsive Shionogi carcinoma 115 by its autonomous subline (Chiba subline 2). Cancer Res 50: 4979-4983, 1990.
10. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, and Sullivan LD: Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 71: 2782-2790, 1993.
11. Klotz LH, Herr HW, Morse MJ, and Whitmore WF: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58: 2546-2550, 1986.
12. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, and Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839-845, 1995.
13. Higano CS, Ellis W, Russell K, and Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48: 800-804, 1996.
14. Foulds L: Neoplastic Development. New York, Academic Press, 1969, vol 1, pp 69-76.
15. Noble RL: Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37: 82-94, 1977.
16. Gleave M, Bruchovsky N, Bowden M, Goldenberg L, and Sullivan LD: Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model (abstract). J Urol 151: 457A, 1994.
17. Umekita Y, Hiipakka RA, Kokontis JM, and Liao S: Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93: 11802-11807, 1996.